An active either changes skin biology or it does not, and a claims file has to show which. GenXMap turns explant and microbiome data into the statistical evidence a claim rests on, with the methods written down well enough to be re-run by someone else.

The questions we take on

Whether an active changes the transcriptome of treated skin, and by how much
Which biological pathways the change actually falls into
Whether the effect holds across donors, or rides on one of them
Whether two formulation iterations differ by more than noise

How the analysis runs

Differential expression

Treated against untreated, with the multiple-testing correction stated rather than implied.

Pathway enrichment

GO, KEGG and gene-set analysis, so a result reads as biology and not as a gene list.

Donor variability

Explant studies are paired designs, and the statistical model says so.

Microbiome community analysis

Composition, diversity and differential abundance on the skin community.

Iteration comparison

The same pipeline, versioned and held fixed across a series, so v1 against v3 is a real comparison.

Working under claims scrutiny

A dermo-cosmetic claim is read by people who did not run the study. Every report carries the exact tool versions, parameters and thresholds used, so the analysis can be audited or reproduced.

Formulation programmes run in cycles. The pipeline is versioned and held fixed across a series, which is the only way a comparison between iterations means anything.

What the report contains

Methods with exact tool versions, parameters and thresholds. QC and cohort-level figures. Statistical results. An interpretation written against the biological question you started from.

Built to be audited or reproduced by a third party.

When the active works through extracellular vesicles

A dermo-cosmetic active that modulates cell communication rather than a single pathway leaves its trace in the vesicles cells release, not only in their own transcriptome. Reading that requires isolating the vesicles, sizing and counting them, and analysing their cargo — three steps, and the first two need instruments worth reaching for rather than duplicating.

The Exosome Characterization Platform is built for exactly that: OMICS4’s isolation and cargo-analysis capacity combined with the specialised nanoparticle-characterization equipment of the Faculté de Pharmacie de Marseille, for higher-resolution sizing, counting and marker validation than either partner reaches alone. The vesicle cargo is then read alongside the transcriptome of the cells that released it, which is where a claim on cell communication becomes defensible.

See the Exosome Characterization Platform

Where the data comes from

The laboratory work behind these analyses runs on OMICS4, GenXMap’s platform site. Sample requirements, shipping and turnaround are published there.

We also take on data we did not generate. An existing dataset, from an earlier study or from another provider, is analysed on its own terms. What decides the work is the question and the metadata that comes with it, not who ran the sequencer.

Book the platforms on OMICS4

Dermatology & Cosmetics